Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
BNTC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q2.23
N/A
-2.83
vs -10.54
Q3.23
N/A
-2.76
vs -7.99
Q4.23
N/A
-2.64
vs -3.40
Q1.24
N/A
-1.64
vs -2.72
Q2.24
N/A
-1.32
vs -2.83
Q3.24
N/A
-0.48
vs -2.76
Q4.24
N/A
-0.36
vs -2.64
Q1.25
N/A
-0.24
vs -1.64
Q2.25
N/A
-0.47
vs -1.32
Q3.25
N/A
-0.69
vs -0.48
Sales Growth
YoY
Current
Estimates
Q4.22
-44%
14K vs 25K
Q1.23
+13%
54K vs 48K
Q2.23
NA
7K vs NA
Q3.23
-100%
NA vs 472K
Q4.23
-100%
NA vs 14K
Q1.24
-89%
6K vs 54K
Q2.24
-100%
NA vs 7K
Q3.24
NA
NA vs NA
Q4.24
NA
NA vs NA
Q1.25
-100%
NA vs 6K
Return on Equity
QoQ
Q2.23
-2307%
-23.07
vs -0.93
Q3.23
-27%
-0.27
vs -23.07
Q4.23
-44%
-0.44
vs -0.27
Q1.24
-37%
-0.37
vs -0.44
Q2.24
-10%
-0.10
vs -0.37
Q3.24
-8%
-0.08
vs -0.10
Q4.24
-10%
-0.10
vs -0.08
Q1.25
-10%
-0.10
vs -0.10
Institutionnal Ownership
QoQ
Q2.23
16
16
vs 20
-20%
Q3.23
12
12
vs 16
-25%
Q4.23
13
13
vs 12
8%
Q1.24
13
13
vs 13
NA
Q2.24
19
19
vs 13
46%
Q3.24
25
25
vs 19
32%
Q4.24
30
30
vs 25
20%
Q1.25
37
37
vs 30
23%
zacks.com
9 hours ago
zacks.com
10 hours ago
zacks.com
10 hours ago
Quote Panel
Key Metrics
Forecast
NaN%2026-Revenue
-938%2026-EPS
-274%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Oppenheimer
initialisePrevious: Not converted
2024-10-15
Now: Outperform
Guggenheim
initialisePrevious: Not converted
2024-09-12
Now: Buy
Piper Sandler
initialisePrevious: Not converted
2024-06-13
Now: Overweight
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
-0.31Â ( -1.97%)
After-hours 15.81$0.37 (2.40%)
Relative Strenght
92
Volume Buzz
126%
Earning Acce
Yes
Dist 52w H.
10%Relative Strength
BNTC
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
